In Fig 5B, none of the MAP kinase (MEK/ERK, JNK or p38 MAPK) inhibitors were able to abrogate PDGF stimulated proliferation in the non PAH HPASMC. This evidence concerns the gene MAP2K7 and pulmonary arterial hypertension.